ArticleAnnals of surgical oncology2026
Surgeon Perspectives on Intraoperative Cell Salvage in Liver Resection for Cancer: A National Survey of Hepatopancreatobiliary Surgeons.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntraoperative cell salvage reduces exposure to allogeneic blood transfusion during major surgery. However, its use in liver resection for cancer remains limited due to concerns regarding tumor-cell dissemination and oncologic safety. The extent to which these concerns influence surgical practice is not well characterized.
methodsWe conducted a national cross-sectional survey of Canadian hepatopancreatobiliary surgeons to assess familiarity, use, and perceptions of IOCS during liver resection for cancer. The anonymous electronic survey was distributed through national HPB networks. Descriptive statistics summarized responses.
resultsTwenty-six HPB surgeons representing 18 Canadian liver surgery programs responded. Most reported moderate/high familiarity with IOCS (23/26) and occasional use in practice (23/26) but use during liver resection for cancer was lower (10/26). Concerns regarding tumor cell contamination were the most frequently cited barrier (13/26). Long-term oncologic outcome data was the factor most commonly identified as increasing confidence in IOCS use (20/26). Most respondents indicated willingness to participate in a clinical trial evaluating oncologic safety (22/26), and all supported guideline incorporation if safety were demonstrated.
conclusionsDespite high familiarity with IOCS, adoption in liver cancer surgery remains limited due to concerns regarding oncologic safety. These findings highlight ongoing clinical equipoise and support the need for high-quality outcome data to guide adoption.
Indexed as
Identifiers
42616331What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.